Cencora (COR) has being experiencing a positive phase in the bio-tech market. The company has consistently shown robust results, outperforming estimates and continuously being appreciated by Wall Street analysts. Main events include
strong Q2 earnings, acquisition of
Retina Consultants of America for $4.6B, and increased FY2025 EPS guidance. Despite some insiders selling stock,
Walgreen's reducing stake, and missing some revenue estimates, the general momentum stays bullish.
Jim Cramer, well-known market commentator, has praised Cencora's middleman strategy and the overall standing of the corporation in the healthcare distribution sector. Raised profit forecasts are a result of a strong demand for specialty drugs, signaling potential for growth. Attention should be directed towards future plans and further acquisition moves as well.
Cencora COR News Analytics from Fri, 12 Jul 2024 05:35:26 GMT to Wed, 21 May 2025 22:35:37 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -7
